Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 28 publications
Neuroimmune Modulation for Drug-Refractory Rheumatoid Arthritis: Long-Term Safety and Efficacy in Patients Enrolled in a Pilot Vagus Nerve Stimulation Study.
Journal: Rheumatology and therapy
Published: August 03, 2025
Correction to: Efficacy, Safety, and Immunogenicity of SDZ-ADL, an Adalimumab Biosimilar, in Biologic-Naïve and Switched Patients with Immune-Mediated Inflammatory Diseases: A Literature Review.
Journal: Advances in therapy
Published: April 28, 2025
Efficacy, Safety, and Immunogenicity of SDZ-ADL, an Adalimumab Biosimilar, in Biologic-Naïve and Switched Patients with Immune-Mediated Inflammatory Diseases: A Literature Review.
Journal: Advances in therapy
Published: September 06, 2024
Understanding immune dysregulation in post-acute sequelae of COVID-19 (PASC)-The hunt for effective treatments.
Journal: The Journal of infection
Published: March 14, 2024
'Totality of Evidence' Approach in the Development of GP2017, an Approved Adalimumab Biosimilar.
Journal: Advances in therapy
Published: December 18, 2023
A plain language summary describing how two different concentrations of GP2017, a biosimilar adalimumab medicine, are associated with similar drug levels within the body.
Journal: Immunotherapy
Published: November 30, 2023
The results of a unique dietary supplement (nutraceutical formulation) used to treat the symptoms of long-haul COVID.
Journal: Frontiers in nutrition
Published: September 01, 2022
Reply to Viel.
Journal: Clinical infectious diseases : an official publication of the Infectious Diseases Society of America
Published: July 12, 2022
Reduced Cell Surface Levels of C-C Chemokine Receptor 5 and Immunosuppression in Long Coronavirus Disease 2019 Syndrome.
Journal: Clinical infectious diseases : an official publication of the Infectious Diseases Society of America
Published: September 23, 2021
Considering Immuno-autonomics in Stratifying Successful Treatment of Rheumatoid Arthritis with Tumor Necrosis Factor Inhibition: Comment on Cohen et al. Rheumatol Ther 2021 June 19.
Journal: Rheumatology and therapy
Published: August 06, 2021
Treatment with SDZ-ADL, an Adalimumab Biosimilar, in Patients with Rheumatoid Arthritis, Psoriasis, or Psoriatic Arthritis: Results of Patient-Reported Outcome Measures from Two Phase III Studies (ADMYRA and ADACCESS).
Journal: BioDrugs : clinical immunotherapeutics, biopharmaceuticals and gene therapy
Published: January 28, 2021
Last Updated: 09/26/2026